27
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): a study protocol for a randomised controlled trial

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Around 35–45 % of people in contact with services for a first episode of psychosis are using cannabis. Cannabis use is associated with delays in remission, poorer clinical outcomes, significant increases in the risk of relapse, and lower engagement in work or education. While there is a clear need for effective interventions, so far only very limited benefits have been achieved from psychological interventions. Contingency management (CM) is a behavioural intervention in which specified desired behavioural change is reinforced through financial rewards. CM is now recognised to have a substantial evidence base in some contexts and its adoption in the UK is advocated by the National Institute for Health and Care Excellence (NICE) guidance as a treatment for substance or alcohol misuse. However, there is currently little published data testing its effectiveness for reducing cannabis use in early psychosis.

          Methods

          CIRCLE is a two-arm, rater-blinded randomised controlled trial (RCT) investigating the clinical and cost-effectiveness of a CM intervention for reducing cannabis use among young people receiving treatment from UK Early Intervention in Psychosis (EIP) services. EIP service users ( n = 544) with a recent history of cannabis use will be recruited. The experimental group will receive 12 once-weekly CM sessions, and a voucher reward if urinalysis shows that they have not used cannabis in the previous week. Both the experimental and the control groups will be offered an Optimised Treatment as Usual (OTAU) psychoeducational package targeting cannabis use. Assessment interviews will be performed at consent, at 3 months, and at 18 months. The primary outcome is time to relapse, defined as admission to an acute mental health service. Secondary outcomes include proportion of cannabis-free urine samples during the intervention period, severity of positive psychotic symptoms, quality-adjusted life years, and engagement in work or education.

          Discussion

          CIRCLE is a RCT of CM for cannabis use in young people with a recent history of psychosis (EIP service users) and recent cannabis use. It is designed to investigate whether the intervention is a clinically and cost-effective treatment for cannabis use. It is intended to inform future treatment delivery, particularly in EIP settings.

          Trial registration

          ISRCTN33576045: doi 10.1186/ISRCTN33576045, registered on 28 November 2011.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

          The variable results of positive-negative research with schizophrenics underscore the importance of well-characterized, standardized measurement techniques. We report on the development and initial standardization of the Positive and Negative Syndrome Scale (PANSS) for typological and dimensional assessment. Based on two established psychiatric rating systems, the 30-item PANSS was conceived as an operationalized, drug-sensitive instrument that provides balanced representation of positive and negative symptoms and gauges their relationship to one another and to global psychopathology. It thus constitutes four scales measuring positive and negative syndromes, their differential, and general severity of illness. Study of 101 schizophrenics found the four scales to be normally distributed and supported their reliability and stability. Positive and negative scores were inversely correlated once their common association with general psychopathology was extracted, suggesting that they represent mutually exclusive constructs. Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The positive and negative syndrome scale (PANSS) for schizophrenia.

            The variable results of positive-negative research with schizophrenics underscore the importance of well-characterized, standardized measurement techniques. We report on the development and initial standardization of the Positive and Negative Syndrome Scale (PANSS) for typological and dimensional assessment. Based on two established psychiatric rating systems, the 30-item PANSS was conceived as an operationalized, drug-sensitive instrument that provides balanced representation of positive and negative symptoms and gauges their relationship to one another and to global psychopathology. It thus constitutes four scales measuring positive and negative syndromes, their differential, and general severity of illness. Study of 101 schizophrenics found the four scales to be normally distributed and supported their reliability and stability. Positive and negative scores were inversely correlated once their common association with general psychopathology was extracted, suggesting that they represent mutually exclusive constructs. Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              EQ-5D: a measure of health status from the EuroQol Group.

              Established in 1987, the EuroQol Group initially comprised a network of international, multilingual and multidisciplinary researchers from seven centres in Finland, the Netherlands, Norway, Sweden and the UK. Nowadays, the Group comprises researchers from Canada, Denmark, Germany, Greece, Japan, New Zealand, Slovenia, Spain, the USA and Zimbabwe. The process of shared development and local experimentation resulted in EQ-5D, a generic measure of health status that provides a simple descriptive profile and a single index value that can be used in the clinical and economic evaluation of health care and in population health surveys. Currently, EQ-5D is being widely used in different countries by clinical researchers in a variety of clinical areas. EQ-5D is also being used by eight out of the first 10 of the top 50 pharmaceutical companies listed in the annual report of Pharma Business (November/December 1999). Furthermore, EQ-5D is one of the handful of measures recommended for use in cost-effectiveness analyses by the Washington Panel on Cost Effectiveness in Health and Medicine. EQ-5D has now been translated into most major languages with the EuroQol Group closely monitoring the process.
                Bookmark

                Author and article information

                Contributors
                s.johnson@ucl.ac.uk
                l.sheridanrains@ucl.ac.uk
                S.Marwaha@warwick.ac.uk
                john.strang@kcl.ac.uk
                thomas.craig@kcl.ac.uk
                t.weaver@mdx.ac.uk
                paul.mccrone@kcl.ac.uk
                michael.king@ucl.ac.uk
                D.Fowler@sussex.ac.uk
                s.pilling@ucl.ac.uk
                l.marston@ucl.ac.uk
                r.omar@ucl.ac.uk
                meghan.ann.craig@gmail.com
                markfhinton@hotmail.com
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                22 October 2016
                22 October 2016
                2016
                : 17
                : 515
                Affiliations
                [1 ]Division of Psychiatry, University College London, London, UK
                [2 ]Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, UK
                [3 ]Addictions Department, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
                [4 ]Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
                [5 ]Mental Health Social Work & Interprofessional Learning,, Middlesex University London, London, UK
                [6 ]Department of Health Services and Population Research, King’s Health Economics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London , London, UK
                [7 ]Department of Psychology, University of Sussex, Brighton, UK
                [8 ]Clinical Psychology and Clinical Effectiveness, University College London, London, UK
                [9 ]Department of Primary Care and Population Health and Priment Clinical Trials Unit, University College London, London, UK
                [10 ]Department of Statistical Science, University College London, London, UK
                Article
                1620
                10.1186/s13063-016-1620-x
                5075422
                27770820
                d90fdfab-ab9f-492b-bb4b-8e0422ae55f8
                © The Author(s). 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 28 April 2016
                : 24 September 2016
                Categories
                Study Protocol
                Custom metadata
                © The Author(s) 2016

                Medicine
                financial incentives,contingency management,cannabis,psychosis,early intervention,substance misuse

                Comments

                Comment on this article